These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 2550637

  • 21. ACE inhibitors in mild to moderate hypertension: comparison of lisinopril and captopril administered once daily. French Cooperative Study Group.
    Gosse P, Dallocchio M, Gourgon R.
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():23-8. PubMed ID: 2550642
    [Abstract] [Full Text] [Related]

  • 22. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril.
    Ajayi AA, Campbell BC, Kelman AW, Howie C, Meredith PA, Reid JL.
    Int J Clin Pharmacol Res; 1985 Jun; 5(6):419-27. PubMed ID: 3005181
    [Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis.
    Kelly JG, Doyle GD, Carmody M, Glover DR, Cooper WD.
    Br J Clin Pharmacol; 1988 Dec; 26(6):781-6. PubMed ID: 2853960
    [Abstract] [Full Text] [Related]

  • 24. The statistical evaluation of a three-period two-treatment crossover pharmacokinetic drug interaction study.
    Ciminera JL, Bolognese JA, Gregg MH.
    Biometrics; 1987 Sep; 43(3):713-8. PubMed ID: 2822158
    [Abstract] [Full Text] [Related]

  • 25. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats.
    Lin JH, Chen IW, Ulm EH, Duggan DE.
    Drug Metab Dispos; 1988 Sep; 16(3):392-6. PubMed ID: 2900730
    [Abstract] [Full Text] [Related]

  • 26. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor.
    Mojaverian P, Rocci ML, Vlasses PH, Hoholick C, Clementi RA, Ferguson RK.
    J Pharm Sci; 1986 Apr; 75(4):395-7. PubMed ID: 3014110
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Lisinopril and nifedipine: no acute interaction in normotensives.
    Lees KR, Reid JL.
    Br J Clin Pharmacol; 1988 Mar; 25(3):307-13. PubMed ID: 2833920
    [Abstract] [Full Text] [Related]

  • 30. ACE inhibition restores the vasodilator potency of the endothelium-derived relaxing factor, L-S-nitrosocysteine, in conscious Spontaneously Hypertensive rats.
    Lewis SJ, Hashmi-Hill MP, Owen JR, Sandock K, Robertson TP, Bates JN.
    Vascul Pharmacol; 2006 Jun; 44(6):491-507. PubMed ID: 16713366
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics of angiotensin converting enzyme inhibition in tissues following oral lisinopril: studies in the rat using quantitative radioinhibitor binding.
    Jackson B, Cubela R, Sakaguchi K, Johnston CI.
    Clin Exp Pharmacol Physiol; 1987 Apr; 14(4):343-7. PubMed ID: 2822313
    [Abstract] [Full Text] [Related]

  • 33. Bioequivalence study of two enalapril maleate tablet formulations in healthy male volunteers. Pharmacokinetic versus pharmacodynamic approach.
    Ribeiro W, Muscará MN, Martins AR, Moreno H, Mendes GB, de Nucci G.
    Eur J Clin Pharmacol; 1996 Apr; 50(5):399-405. PubMed ID: 8839663
    [Abstract] [Full Text] [Related]

  • 34. Lisinopril: a nonsulfhydryl angiotensin-converting enzyme inhibitor.
    Noble TA, Murray KM.
    Clin Pharm; 1988 Sep; 7(9):659-69. PubMed ID: 2853660
    [Abstract] [Full Text] [Related]

  • 35. Interaction between oral hydralazine and propranolol. I. Changes in absorption, presystemic clearance and splanchnic blood flow.
    Heinzow B, Corbett H, Constantinides S, Bourne R, McLean AJ.
    J Pharmacol Exp Ther; 1984 May; 229(2):509-14. PubMed ID: 6716273
    [Abstract] [Full Text] [Related]

  • 36. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.
    Westendorp B, Schoemaker RG, van Gilst WH, van Veldhuisen DJ, Buikema H.
    Eur J Pharmacol; 2005 Dec 19; 527(1-3):141-9. PubMed ID: 16310764
    [Abstract] [Full Text] [Related]

  • 37. Kinetic and metabolic aspects of enalapril action.
    Lant AF, McNabb RW, Noormohamed FH.
    J Hypertens Suppl; 1984 Dec 19; 2(2):S37-42. PubMed ID: 6100875
    [Abstract] [Full Text] [Related]

  • 38. Effects of the angiotensin converting enzyme inhibitor, lisinopril, on normal and diabetic rats.
    Hartmann JF, Szemplinski M, Hayes NS, Keegan ME, Slater EE.
    J Hypertens; 1988 Aug 19; 6(8):677-83. PubMed ID: 2846685
    [Abstract] [Full Text] [Related]

  • 39. Lisinopril pharmacokinetics in chronic renal failure.
    Jackson B, Cubela RB, Conway EL, Johnston CI.
    Br J Clin Pharmacol; 1988 Jun 19; 25(6):719-24. PubMed ID: 2849471
    [Abstract] [Full Text] [Related]

  • 40. Drug interaction of spirapril hydrochloride monohydrate and hydrochlorothiazide. A clinical study to compare the pharmacokinetics after administration of spirapril hydrochloride monohydrate tablets, hydrochlorothiazide tablets and fixed combination bi-layer tablets.
    Schürer M, Erb K, Junge K, Schäfer HF, Schulz HU, Amschler S, Krupp S, Hermann R.
    Arzneimittelforschung; 2003 Jun 19; 53(6):414-9. PubMed ID: 12872612
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.